依维莫司治疗神经内分泌肿瘤：最新结果与临床潜力
Everolimus treatment for neuroendocrine tumors: latest results and clinical potential.
作者信息
Pusceddu Sara, Verzoni Elena, Prinzi Natialie, Mennitto Alessia, Femia Daniela, Grassi Paolo, Concas Laura, Vernieri Claudio, Lo Russo Giuseppe, Procopio Giuseppe
机构信息
Medical Oncology, Istituto Nazionale Tumori, Milan, Italy.
Medical Oncology, Istituto Nazionale Tumori, Via Venezian 1, 20100, Milan, Italy.
出版信息
Ther Adv Med Oncol. 2017 Mar;9(3):183-188. doi: 10.1177/1758834016683905. Epub 2017 Jan 11.
Abstract
Neuroendocrine tumors (NETs) are a heterogeneous class of diseases characterized by challenging management. Preclinical evidence shows that the PI3K/AKT/mTOR signaling pathway plays a central role in the pathogenesis and progression of NETs. Everolimus is a direct inhibitor of this pathway, and therefore this molecule appears to be a well-grounded strategy for the treatment of NETs, capable of changing clinical practice. The efficacy and safety of everolimus was demonstrated in the RADIANT trials. In this work, we comment on the results of the RADIANT trials, and other recent key evidence from fully published clinical trials on everolimus, and we discuss the current role of everolimus in the treatment of NETs.
摘要
神经内分泌肿瘤（NETs）是一类异质性疾病，其治疗颇具挑战性。临床前证据表明，PI3K/AKT/mTOR信号通路在NETs的发病机制和进展中起核心作用。依维莫司是该通路的直接抑制剂，因此该分子似乎是治疗NETs的一个有充分依据的策略，有望改变临床实践。依维莫司的疗效和安全性在RADIANT试验中得到了证实。在本文中，我们对RADIANT试验的结果以及其他有关依维莫司的已充分发表的临床试验的近期关键证据进行评论，并讨论依维莫司在NETs治疗中的当前作用。
相似文献
1
Everolimus treatment for neuroendocrine tumors: latest results and clinical potential.依维莫司治疗神经内分泌肿瘤：最新结果与临床潜力
Ther Adv Med Oncol. 2017 Mar;9(3):183-188. doi: 10.1177/1758834016683905. Epub 2017 Jan 11.
2
How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies.RADIANT试验的结果如何影响神经内分泌肿瘤（NET）患者的管理？对已发表研究的系统评价。
Oncotarget. 2016 Jul 12;7(28):44841-44847. doi: 10.18632/oncotarget.8601.
3
Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature.依维莫司治疗胰腺外神经内分泌肿瘤的疗效与安全性：文献综述
Oncologist. 2016 Jul;21(7):875-86. doi: 10.1634/theoncologist.2015-0420. Epub 2016 Apr 6.
4
Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.依维莫司、镥[177Lu]DOTATATE 和舒尼替尼治疗晚期、不可切除或转移性神经内分泌肿瘤且疾病进展：系统评价和成本效果分析。
Health Technol Assess. 2018 Sep;22(49):1-326. doi: 10.3310/hta22490.
5
Everolimus in the management of metastatic neuroendocrine tumours.依维莫司用于转移性神经内分泌肿瘤的治疗
Therap Adv Gastroenterol. 2017 Jan;10(1):132-141. doi: 10.1177/1756283X16674660. Epub 2016 Oct 25.
6
Safety and efficacy of everolimus in adult patients with neuroendocrine tumors.依维莫司在成人神经内分泌肿瘤患者中的安全性和疗效。
Clin Med Insights Oncol. 2012;6:41-51. doi: 10.4137/CMO.S7319. Epub 2012 Jan 4.
7
Emerging use of everolimus in the treatment of neuroendocrine tumors.依维莫司在神经内分泌肿瘤治疗中的新应用。
Cancer Manag Res. 2017 Jun 20;9:215-224. doi: 10.2147/CMAR.S113382. eCollection 2017.
8
The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy?mTOR 在神经内分泌肿瘤中的作用：未来制胜策略的基石？
Int J Mol Sci. 2018 Mar 6;19(3):747. doi: 10.3390/ijms19030747.
9
Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations.依维莫司治疗晚期胰腺神经内分泌肿瘤患者：最新研究结果及解读。
Therap Adv Gastroenterol. 2013 Sep;6(5):412-9. doi: 10.1177/1756283X13496970.
10
Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?依维莫司对人胰腺神经内分泌肿瘤原代培养物的抗增殖和抗分泌作用：与生长抑素类似物联合使用是否有益？
Oncotarget. 2017 Jun 20;8(25):41044-41063. doi: 10.18632/oncotarget.17008.
引用本文的文献
1
Hypoxia drives CBR4 down-regulation promotes gastroenteropancreatic neuroendocrine tumors via activation mammalian target of rapamycin mediated by fatty acid synthase.缺氧驱动CBR4下调，通过脂肪酸合酶介导的雷帕霉素哺乳动物靶标激活促进胃肠胰腺神经内分泌肿瘤。
J Cell Commun Signal. 2024 Jun 22;18(3):e12041. doi: 10.1002/ccs3.12041. eCollection 2024 Sep.
2
The Role of Inositols in Endocrine and Neuroendocrine Tumors.肌醇在内分泌和神经内分泌肿瘤中的作用。
Biomolecules. 2024 Aug 14;14(8):1004. doi: 10.3390/biom14081004.
3
Incidentally Found Rectal Carcinoid Tumor in a 46-Year-Old Female: The Potential for Complications and the Importance of Screening Guidelines.46岁女性偶然发现的直肠类癌肿瘤：并发症的可能性及筛查指南的重要性
Cureus. 2024 Feb 28;16(2):e55163. doi: 10.7759/cureus.55163. eCollection 2024 Feb.
4
Comparative Survival Benefits of Surgery and Adjuvant Chemotherapy in Neuroendocrine Carcinoma of the Gallbladder: A Population-Based Study with Insight into Future Personalized Therapeutic Approach.胆囊神经内分泌癌手术与辅助化疗的比较生存获益：一项基于人群的研究及对未来个性化治疗方法的洞察
J Pers Med. 2023 Jun 18;13(6):1009. doi: 10.3390/jpm13061009.
5
Values of debulking surgery for unresectable well-differentiated metastatic pancreatic neuroendocrine tumors: a comparative study.减瘤手术对无法切除的高分化转移性胰腺神经内分泌肿瘤的价值：一项比较研究。
Gastroenterol Rep (Oxf). 2023 Mar 8;11:goad010. doi: 10.1093/gastro/goad010. eCollection 2023.
6
Emerging Immunotherapeutic and Diagnostic Modalities in Carcinoid Tumors.类癌肿瘤的新兴免疫治疗和诊断方法。
Molecules. 2023 Feb 22;28(5):2047. doi: 10.3390/molecules28052047.
7
Role of Somatostatin Signalling in Neuroendocrine Tumours.生长抑素信号在神经内分泌肿瘤中的作用。
Int J Mol Sci. 2022 Jan 27;23(3):1447. doi: 10.3390/ijms23031447.
8
Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors.局部进展期胰腺神经内分泌肿瘤手术治疗效果评价。
JAMA Netw Open. 2020 Nov 2;3(11):e2024318. doi: 10.1001/jamanetworkopen.2020.24318.
9
Surgical management of primary pancreatic neuroendocrine tumors.原发性胰腺神经内分泌肿瘤的外科治疗
J Gastrointest Oncol. 2020 Jun;11(3):578-589. doi: 10.21037/jgo.2019.12.09.
10
Paraganglion, a pitfall in diagnosis after regular cholecystectomy.副神经节瘤，常规胆囊切除术后诊断中的一个陷阱。
Int J Surg Case Rep. 2019;65:205-208. doi: 10.1016/j.ijscr.2019.10.042. Epub 2019 Oct 28.
本文引用的文献
1
How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies.RADIANT试验的结果如何影响神经内分泌肿瘤（NET）患者的管理？对已发表研究的系统评价。
Oncotarget. 2016 Jul 12;7(28):44841-44847. doi: 10.18632/oncotarget.8601.
2
Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.二甲双胍联合依维莫司和奥曲肽用于糖尿病胰腺神经内分泌肿瘤患者
Future Oncol. 2016 May;12(10):1251-60. doi: 10.2217/fon-2015-0077. Epub 2016 Feb 18.
3
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.依维莫司治疗晚期肺或胃肠道无功能性神经内分泌肿瘤（RADIANT-4）：一项随机、安慰剂对照的3期研究。
Lancet. 2016 Mar 5;387(10022):968-977. doi: 10.1016/S0140-6736(15)00817-X. Epub 2015 Dec 17.
4
Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial.既往使用生长抑素类似物对晚期神经内分泌肿瘤患者依维莫司活性的影响：来自III期RADIANT-2试验的分析
Neuroendocrinology. 2015;102(1-2):18-25. doi: 10.1159/000381715. Epub 2015 Mar 21.
5
Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.MetNET-1试验的原理与方案，这是一项前瞻性、单中心、II期研究，旨在评估依维莫司联合长效奥曲肽和二甲双胍用于晚期胰腺神经内分泌肿瘤患者的活性和安全性。
Tumori. 2014 Nov-Dec;100(6):e286-9. doi: 10.1700/1778.19298.
6
Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.既往化疗用药对依维莫司治疗晚期胰腺神经内分泌肿瘤患者疗效的影响：III期RADIANT-3试验的亚组分析
Pancreas. 2015 Mar;44(2):181-9. doi: 10.1097/MPA.0000000000000262.
7
Real-world study of everolimus in advanced progressive neuroendocrine tumors.依维莫司治疗晚期进展性神经内分泌肿瘤的真实世界研究。
Oncologist. 2014 Sep;19(9):966-74. doi: 10.1634/theoncologist.2014-0037. Epub 2014 Aug 12.
8
PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy.甲状腺髓样癌中的PI3K/Akt/mTOR信号传导：一种有前景的癌症治疗分子靶点。
Endocrine. 2015 Mar;48(2):363-70. doi: 10.1007/s12020-014-0380-1. Epub 2014 Aug 13.
9
Medical treatment of advanced thoracic neuroendocrine tumors.晚期胸部神经内分泌肿瘤的治疗。
Thorac Surg Clin. 2014 Aug;24(3):351-5. doi: 10.1016/j.thorsurg.2014.05.006.
10
Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.依维莫司联合长效可重复注射奥曲肽用于神经内分泌肿瘤患者一线治疗：一项国际多中心肿瘤学研究组织（ITMO）小组的研究
Cancer. 2014 Aug 15;120(16):2457-63. doi: 10.1002/cncr.28726. Epub 2014 Apr 18.
Zotero 插件